Vaccine · Immune activation · developed by Osivax
OVX836 is an agent given as a single intramuscular administration on Day 1 in trials in influenza and vaccine-preventable diseases.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06582277 | Phase 2 | Vaccine-Preventable Diseases | Completed | HRMY |
| NCT05284799 | Phase 2 | Influenza | Completed | HRMY |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
InfluenzaVaccine-Preventable Diseases